Recombinant multi-species CPT1A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CPT1A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The mitochondrial oxidation of long-chain fatty acids is initiated by the sequential action of carnitine palmitoyltransferase I (which is located in the outer membrane and is detergent-labile) and carnitine palmitoyltransferase II (which is located in the inner membrane and is detergent-stable), together with a carnitine-acylcarnitine translocase. CPT I is the key enzyme in the carnitine-dependent transport across the mitochondrial inner membrane and its deficiency results in a decreased rate of fatty acid beta-oxidation. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
The Alternative Names of target: C730027G07,CPT-Ia,CPT1,CPT1-L,CPT1A,CPTI,CPTI-L),Carnitine O-palmitoyltransferase 1,Carnitine O-palmitoyltransferase I,Carnitine palmitoyltransferase 1A,Cpt1,Cpt1a,L-CPT1,Succinyltransferase CPT1A,liver isoform,liver isoform (CPT I

Target products collectionGo to CPT1A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP0608-Ag-1/ GM-Tg-hg-IP0608-Ag-2 Human CPT1A protein Human
GM-Tg-rg-IP0608-Ag-1/ GM-Tg-rg-IP0608-Ag-2 Rat CPT1A protein Rat
GM-Tg-mg-IP0608-Ag-1/ GM-Tg-mg-IP0608-Ag-2 Mouse CPT1A protein Mouse
GM-Tg-cynog-IP0608-Ag-1/ GM-Tg-cynog-IP0608-Ag-2 Cynomolgus/Rhesus macaque CPT1A protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP0608-Ag-1/ GM-Tg-felg-IP0608-Ag-2 Feline CPT1A protein Feline
GM-Tg-cang-IP0608-Ag-1/ GM-Tg-cang-IP0608-Ag-2 Canine CPT1A protein Canine
GM-Tg-bovg-IP0608-Ag-1/ GM-Tg-bovg-IP0608-Ag-2 Bovine CPT1A protein Bovine
GM-Tg-equg-IP0608-Ag-1/ GM-Tg-equg-IP0608-Ag-2 Equine CPT1A protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP0608-Ag-1/ GM-Tg-hg-IP0608-Ag-2; GM-Tg-rg-IP0608-Ag-1/ GM-Tg-rg-IP0608-Ag-2;
GM-Tg-mg-IP0608-Ag-1/ GM-Tg-mg-IP0608-Ag-2; GM-Tg-cynog-IP0608-Ag-1/ GM-Tg-cynog-IP0608-Ag-2;
GM-Tg-felg-IP0608-Ag-1/ GM-Tg-felg-IP0608-Ag-2; GM-Tg-cang-IP0608-Ag-1/ GM-Tg-cang-IP0608-Ag-2;
GM-Tg-bovg-IP0608-Ag-1/ GM-Tg-bovg-IP0608-Ag-2; GM-Tg-equg-IP0608-Ag-1/ GM-Tg-equg-IP0608-Ag-2
Products Name CPT1A protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name CPT1A
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CPT1A protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.